Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Tuesday, October 20, 2026

⚡ Executive Takeaway

China's draft export rules are not final, and Monday's dealmaking already obeys them. Roche committed $400 million upfront to Hansoh for ADCs built on Hansoh's engine against targets Roche picks, and left the engine, the early clinic, and Greater China in Shanghai. Lilly signed Hong Kong's Metis for AI designed lipid nanoparticles on the same terms of trade: discovery output for milestones, with the platform staying home. The same morning, Merck KGaA bought a Western siRNA company outright, the exact transaction the draft would forbid for a Chinese siRNA platform. That is the new two lane market. In China, big pharma rents an engine's output and pays for it upfront, because no acquisition premium waits at the exit. Outside China, platforms stay buyable, and the premium, 130% at Silence, goes to whoever owns one. For a Chinese platform company, value now lives in recurring deal flow rather than a sale. For a Western BD team, the cheapest optionality in the market is a target nomination slot on someone else's engine. Price China platform deals as subscriptions, not acquisitions.

Full deal terms, the trial tables, and the day's movers, all below. 👉 Read Full Analysis

🇨🇳 China and Global

Roche paid $400 million upfront to use Hansoh's ADC engine without owning it, the first big China deal since Beijing drew its draft line. RHHBY | Hansoh Pharma | LLY

Per Hansoh's release, the agreement covers two preclinical Hansoh ADCs plus multiple programs on targets Roche proposes, with Hansoh running development through global Phase Ia and keeping all rights in mainland China, Hong Kong, Macau, and Taiwan. Hansoh can also pick up to two programs to co develop outside China for a share of US upside. Endpoints News counts it as Roche's sixth China deal since August. Lilly's discovery pact with Hong Kong's Metis TechBio follows the same pattern at smaller scale, up to about $1.1 billion with a low double digit million upfront, per Fierce Biotech and Reuters; Metis's own filing was not retrieved, so those figures stay attributed. The draft rules, as Fierce reported them Friday, ban foreign acquisition of certain Chinese platforms and leave out licensing alone. Monday's three platform deals sorted along exactly that line:

🧬 RNA and M&A

Merck KGaA paid a 130% premium for an siRNA company, the kind of platform purchase China's draft would ban at home. SLN | Merck KGaA

The offer is $20.00 in cash per ADS, about $1.3 billion in equity value and $1.1 billion in enterprise value, through a UK scheme of arrangement expected to close in the first quarter of 2027, per the companies' release. The prize is divesiran, an siRNA for polycythemia vera dosed every 12 weeks, positioned against the weekly injection of Takeda and Protagonist's Mimrylo; Fierce Biotech reported an 88% Phase 2 response rate. Silence closed at 19.58, 2.1% under the offer, our arithmetic. One footnote for the China file: Fierce noted that Hansoh had earlier exited Silence's zerlasiran collaboration.

💊 Rare Disease

Disc Medicine turned a complete response letter into a clean Phase 3 sweep, and its resubmission now looks like execution rather than argument. IRON

APOLLO randomized 183 patients aged 12 and up with erythropoietic protoporphyria to bitopertin 60 mg or placebo for six months. Bitopertin cut whole blood PPIX 41.4% versus placebo and added 12.2 hours a month of time in light without pain at month 6, and every secondary endpoint hit, per Disc's release. Dizziness was the most common side effect at 50%, mostly mild or moderate and transient, with nothing above Grade 3. Disc plans to resubmit its NDA by the end of 2026 and expects a decision by mid 2027. IRON rose 38.9% to 78.93, our arithmetic.

💇 Dermatology

Veradermics' oral minoxidil won its second Phase 3, and the dose it files is now the commercial question. MANE

Study 304, a new trial distinct from April's study 302, enrolled 536 men with mild to moderate pattern hair loss. At month 6 the twice daily dose added 36.4 hairs per cm² and the once daily dose 28.6, versus 6.6 on placebo, with patient rated improvement of 68.7%, 55.7%, and 15.0%, per the company. The catch sits in the safety table: hypertrichosis ran 9.0% on twice daily versus 2.2% once daily, and peripheral edema 4.5% versus 2.8%. The release gave no NDA timing. MANE rose 12.4% to 122.28, ours.

🧪 Oncology

Jemperli became the first immunotherapy approved for locally advanced rectal cancer, and most responders avoided surgery. GSK

The FDA granted accelerated approval to dostarlimab as a single agent for adults with stage II or III, MSI-H/dMMR locally advanced rectal cancer, per GSK. In the single arm AZUR-1 trial of 154 patients, 68% had a sustained clinical complete response at 12 months by investigator review, and 47% by central review with data still maturing; no responder has recurred at a median follow up beyond two years. Continued approval may depend on a confirmatory trial. The news crossed after the close, so Tuesday is GSK's first reaction session.

🩺 Medtech

Automated insulin delivery gained another Type 2 entrant two days before Abbott reports on its diabetes business. Sequel Med Tech (private) | ABT

Sequel disclosed Friday that the FDA cleared its twiist automated insulin delivery system for adults with insulin treated Type 2 diabetes, extending a March 2024 Type 1 clearance, per MedTech Dive. The system runs on the Tidepool Loop algorithm and pairs with Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365. In a 13 week trial of 307 adults, A1C fell 0.7 points and time in range rose from 57% to 73%, per Healio. It lands in a Type 2 market already contested by Insulet, Tandem, Beta Bionics, and a newly independent MiniMed, and Abbott's Wednesday print is the first read on how much sensor demand that competition is creating.

📋 Quick Hits

👀 What To Watch Today

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

© 2026 BioMed Nexus. All rights reserved.